{"name":"Foghorn Therapeutics","slug":"foghorn","ticker":"FHTX","exchange":"NASDAQ","domain":"foghorntx.com","description":"Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.","hq":"Cambridge, MA","founded":0,"employees":"106","ceo":"Adrian Gottschalk","sector":"Oncology / Chromatin Biology","stockPrice":4.08,"stockChange":-0.09,"stockChangePercent":-2.16,"marketCap":"$240M","metrics":{"revenue":30909000,"revenueGrowth":-45.1,"grossMargin":-190.9,"rdSpend":85466000,"netIncome":-74283000,"cash":183631008,"dividendYield":0,"peRatio":-4.4,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-15","type":"earnings","headline":"Foghorn Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"Foghorn Therapeutics reported its fourth quarter and full year 2022 financial results, with a net loss of $24.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2022-06-14","type":"deal","headline":"Foghorn Therapeutics Announces Collaboration with Merck KGaA to Develop Oncology Therapies","summary":"Foghorn Therapeutics announced a collaboration with Merck KGaA to develop oncology therapies targeting chromatin regulators.","drugName":"","sentiment":"positive"},{"date":"2022-03-15","type":"trial","headline":"Foghorn Therapeutics Announces Initiation of Phase 1 Clinical Trial of FTX-6058","summary":"Foghorn Therapeutics announced the initiation of a Phase 1 clinical trial of FTX-6058, a small molecule inhibitor of the chromatin regulator protein BRD4.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE8wUF9VUjAtQnFvVklhMTl2bVdHd1czaENoZWdHOG16WVJ0UzN6YWpQbG43Zk5qSmtuRHZoODNYRlMxWmFTUkxNQVFGZFVJMTdFM2VlbC12X0FzQ1lqN0tWNVlhZGR0eVJfYmJQVWtR?oc=5","date":"2026-04-08","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Foghorn Therapeutics Inc. (FHTX) - Stock Titan","headline":"If You Invested $1,000 in Foghorn Therapeutics Inc. (FHTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1FRnI3MFhubm93NEZvTGdlWHRTV25oSzVtWERHeGFXSnNfV1FzU0tjUi1CdHc0WEhZZ2N6UGVST3dMQjQ4SHRKejJNd0RzRmlJLW5jSlF6THdJWmdkNHI0?oc=5","date":"2026-04-02","type":"pipeline","source":"ChartMill","summary":"FHTX Stock Price, Quote & Chart | FOGHORN THERAPEUTICS INC (NASDAQ:FHTX) - ChartMill","headline":"FHTX Stock Price, Quote & Chart | FOGHORN THERAPEUTICS INC (NASDAQ:FHTX)","sentiment":"neutral"},{"date":"2026-03-11","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxORHVsTUJncm5UX1llaGxyM2ROaFNadjJweGk3SzFRdHUtZVhRZkJlSmZadnlNQWlaNm9MRDFuWmlXZjZzU1NWUEtoZ0NjTHYyZUNELVVTdWQzZG43cmZBTzBBUm9IalVfUDNIYmp3ZUJxVnd5NWJmNEZTSXE0blQtdU9rc0JJMGt6Y0RSaGp6LVN4YzVFTXF3cHZhaTRLRUgwVU9IU1VUUnl6c1VlUEd2NUNvMmtlWVR2YVhubi1LYkNxaENnQ21NTGVtRnVXRVBrRTdNemJn?oc=5","date":"2026-02-24","type":"pipeline","source":"The Globe and Mail","summary":"Foghorn Therapeutics Names Veteran Executive as New CFO - The Globe and Mail","headline":"Foghorn Therapeutics Names Veteran Executive as New CFO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOWWc3MFZBNFZLaUdBUjFlLWpzMGFrVWN6Qm5DMW40SG1mV3ZxQy0yOUNZN1E0VlhsVllNU2JtNHNOZmFxdU1rMzBhSFlVREY5MzVTVlRZWGdyRVV1TU8temI5V2Y2V1JVM0dTVkVsNExWZUlEYlZTNGhEbXg5YmtBdEd1cUlBZXk5dmdlX1ItT0hUdm1BWk56ZDRERHBuQndINC1DZi1HSi1adEE?oc=5","date":"2026-02-23","type":"pipeline","source":"Quiver Quantitative","summary":"Foghorn Therapeutics Inc. Appoints Ryan Maynard as Chief Financial Officer - Quiver Quantitative","headline":"Foghorn Therapeutics Inc. Appoints Ryan Maynard as Chief Financial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQVFZuMXBfc0hqNE5yTDZCWERBWmxzWko4MGphUGxYSlJadFBfc3lRRWNsT1o2LVJCb1BxVUNDc3BKa1F5NFlCWHpQMFdDR0R2OXc3UE1aNUdTTDZzYldGbXQyZzVpcEdxSVdTc2NuTUd1UjFaaGc3TFo5Z0sxXzAzWEc0alVYV1hnTlJITFJuMUl6eU1BTEFzd3dybXgtY3Rtd0JTbUxoYTg3bEZtWThERkFRRQ?oc=5","date":"2026-02-23","type":"deal","source":"Stock Titan","summary":"Biotech CFO who raised $1B in deals joins Foghorn Therapeutics - Stock Titan","headline":"Biotech CFO who raised $1B in deals joins Foghorn Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxOVVFmdmZIb2RRNjljc1phU0cwX01mT1lUUW5rU01KaHhBcy1MYlU3d3NkTXR5em9ta2R4cXdYUGNfM094WDlFSVY0T3hXUmtvSGRFdkY4VDJpcjV4aGZWTjdiOGRoZ1p4aFl0ZDF1YUtZSnlST2YzLTRTdk5YYUZQQkh4dk5yRVVkY2hubWhXQXY1MlkyQWF1V3NydDZMYnkyS2JoV1lNdTBwZ1VoWlZUejhVaTZVaWVSaHlTc1M3MU1WSGZPX3RBSTZmMmowaFhOaFFfUGlfUG9YMmp6Njd3Tmp4N0s2SUdqQnpCeTNIdzlLaHdXeFkxOEhMbm0xcENvc1VubjRBblJ1OTJuVFJXX3p5WQ?oc=5","date":"2026-02-23","type":"pipeline","source":"globenewswire.com","summary":"Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer - globenewswire.com","headline":"Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer","sentiment":"neutral"},{"date":"2026-02-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQMVZUeWV1VnVNQWI0Tkw1U0Q1QnppUWI5SVNDemU1Ump0ZlNsa2g0dmZ4MFh1TWZIdWFXcWZ5LWU4c2VHY3Vib3p0ZmRaVkxfVF9SRkEtdTU1a3Q3d3hwTFJvQmpLUWNfakt2Tm5STk5hUmRiYkxqMk5JVlVxNVNLTHJOMF9WbVBJRGlxT3NWdUE1anRPLVJlRVlBZWZUSk9zOGRmbUxwbC1sTHM?oc=5","date":"2026-02-13","type":"pipeline","source":"Seeking Alpha","summary":"The top performing pharma and biotech stocks as group sees resurgence (PJP:NYSEARCA) - Seeking Alpha","headline":"The top performing pharma and biotech stocks as group sees resurgence (PJP:NYSEARCA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxNNGVpUFhJZW9tODl4ZFRiMGM5NDljUW9LRHppUVM2bXBVbFhUMEVWX1RCanQ3dWt5WV9URl9zLVVaVVpJa0lIbUNNYTNnRGduRE5iTGoyeUlNSm9zQ2ROSkZDZmQ4QUF3R0cyWTIzcTFBX1BTRXRYLU5kSVBFdnJMNi1CX1dLWm5tdEdoLU5UUVplOFdhUEVuZ1pvX3JnZFRWYVgwY0RmV1JSdWhMZVhSdTBJX3VTZ25EYzhBUkl3NkpyRTdxNXZybXhoZ1NreTZ6RWgxb3FtSVVKSXJLVTRvVEZkME1zS2VKdUFGWVdlZENfUnd3d3owdjBnMkdfdC1y?oc=5","date":"2026-01-27","type":"pipeline","source":"The Globe and Mail","summary":"Hard-to-Treat Cancers: How 2026’s Top Clinical Platforms Are Beating Industry Benchmarks - The Globe and Mail","headline":"Hard-to-Treat Cancers: How 2026’s Top Clinical Platforms Are Beating Industry Benchmarks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxOQWsxaTRKZHdTalhSWlJUYUsyLVpibzZNNzE2SjludWlxay1xQVRIT2lGOVpXUGxDOWZhdVl2UGZJbGhuZUxodk5WWlFzV2h5SXc4SXFWTkxXeDdWUmUxczMwU2I5QnlrOXpwT1BLY0NwNnhyZ3o5M0luVzZLTy12bkU0S0VMS2tocHBTc0I2SjVjbEhvUnYwZnVRRTktMXRKSjgyVXlSbE5qTlRwRmtmWGdPMmdpeUZ2TmNCeERPaXl1SXNieFRGZkNvTHA2Wl9yUmc?oc=5","date":"2026-01-14","type":"patent","source":"PR Newswire","summary":"Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - PR Newswire","headline":"Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-19","type":"pipeline","source":"simplywall.st","summary":"Here's Why We're Watching Foghorn Therapeutics' (NASDAQ:FHTX) Cash Burn Situation - simplywall.st","headline":"Here's Why We're Watching Foghorn Therapeutics' (NASDAQ:FHTX) Cash Burn Situation","sentiment":"neutral"},{"date":"2025-12-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","AstraZeneca"],"therapeuticFocus":["Oncology","Chromatin Biology"],"financials":{"source":"sec_edgar+yahoo","revenue":30909000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":30909000,"period":"2025-12-31"},{"value":22602000,"period":"2024-12-31"},{"value":22602000,"period":"2024-12-31"},{"value":34155000,"period":"2023-12-31"},{"value":34155000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":85466000,"rdSpendHistory":[{"period":"2025-12-31","value":85466000},{"period":"2024-12-31","value":94528000},{"period":"2023-12-31","value":109689000},{"period":"2022-12-31","value":105618000}],"sgaSpend":27550000,"operatingIncome":-82107000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-82107000},{"period":"2024-12-31","value":-100285000},{"period":"2023-12-31","value":-107906000},{"period":"2022-12-31","value":-117137000}],"netIncome":-74283000,"netIncomeHistory":[{"period":"2025-12-31","value":-74283000},{"period":"2024-12-31","value":-86620000},{"period":"2023-12-31","value":-98426000},{"period":"2022-12-31","value":-108882000}],"eps":-1.58,"epsHistory":[{"period":"2024-12-31","value":-1.58},{"period":"2023-12-31","value":-2.34},{"period":"2022-12-31","value":-2.62},{"period":"2021-12-31","value":-2.73}],"cash":80876000,"cashHistory":[{"period":"2025-12-31","value":80876000},{"period":"2024-12-31","value":55454000},{"period":"2023-12-31","value":80336000},{"period":"2022-12-31","value":52214000}],"totalAssets":198103000,"totalLiabilities":306603000,"totalDebt":41270000,"equity":-108500000,"operatingCashflow":-86099000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-86099000},{"period":"2024-12-31","value":-100406000},{"period":"2023-12-31","value":-118106000},{"period":"2022-12-31","value":193612000}],"capex":-50000,"capexHistory":[{"period":"2025-12-31","value":-50000},{"period":"2024-12-31","value":-906000},{"period":"2023-12-31","value":-1224000},{"period":"2022-12-31","value":-1210000}],"freeCashflow":-86149000,"dividendsPaid":null,"buybacks":null,"employees":106,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":6797000,"ebit":-19596000,"ebitda":-18794000,"period":"2025-12-31","revenue":9247000,"epsBasic":null,"netIncome":-21664000,"rdExpense":22046000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-19596000},{"sga":6652000,"ebit":-18501000,"ebitda":-17649000,"period":"2025-09-30","revenue":8153000,"epsBasic":-0.25,"netIncome":-15849000,"rdExpense":20002000,"epsDiluted":-0.25,"grossProfit":null,"operatingIncome":-18501000},{"sga":6862000,"ebit":-21097000,"ebitda":-20246000,"period":"2025-06-30","revenue":7557000,"epsBasic":-0.28,"netIncome":-17936000,"rdExpense":21792000,"epsDiluted":-0.28,"grossProfit":null,"operatingIncome":-21097000},{"sga":7239000,"ebit":-22913000,"ebitda":-22086000,"period":"2025-03-31","revenue":5952000,"epsBasic":-0.3,"netIncome":-18834000,"rdExpense":21626000,"epsDiluted":-0.3,"grossProfit":null,"operatingIncome":-22913000},{"sga":6353000,"ebit":-24005000,"ebitda":-23244000,"period":"2024-12-31","revenue":2856000,"epsBasic":null,"netIncome":-19503000,"rdExpense":20508000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-24005000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.31,"netIncome":null,"rdExpense":null,"epsDiluted":-0.31,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":4.08,"previousClose":4.17,"fiftyTwoWeekHigh":6.95,"fiftyTwoWeekLow":3.27,"fiftyTwoWeekRange":"3.27 - 6.95","fiftyDayAverage":4.94,"twoHundredDayAverage":5.01,"beta":2.97,"enterpriseValue":103200056,"forwardPE":-4.4,"priceToBook":-2.13,"priceToSales":8.49,"enterpriseToRevenue":3.66,"enterpriseToEbitda":-1.32,"pegRatio":0,"ebitda":-78024000,"ebitdaMargin":-276.4,"freeCashflow":-36926376,"operatingCashflow":-87397000,"totalDebt":41994000,"debtToEquity":0,"currentRatio":2.92,"returnOnAssets":-21,"returnOnEquity":0,"analystRating":"1.1 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":9,"targetMeanPrice":11.44,"targetHighPrice":14,"targetLowPrice":9,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":17.9,"institutionHeldPercent":72.7,"sharesOutstanding":58713922,"floatShares":28687622,"sharesShort":1357915,"shortRatio":10.56,"shortPercentOfFloat":2.3,"epsTrailing":-1.17,"epsForward":-0.93,"revenuePerShare":0.44,"bookValue":-1.92,"officers":[{"age":49,"name":"Mr. Adrian H. B. Gottschalk","title":"President, CEO & Director"},{"age":60,"name":"Dr. Steven F. Bellon Ph.D.","title":"Chief Scientific Officer"},{"age":54,"name":"Dr. Alfonso Quintas Cardama M.D.","title":"Chief Medical Officer"},{"age":null,"name":"Dr. Gerald R. Crabtree M.d.","title":"Founder & Member of Scientific Advisory Board"},{"age":56,"name":"Mr. Ryan D. Maynard","title":"Chief Financial Officer"},{"age":null,"name":"Ms. Karin  Hellsvik","title":"Chief of Staff to the CEO, VP, Head of Corporate Affairs, Investor Relations & Operations"},{"age":60,"name":"Mr. Michael J. LaCascia J.D.","title":"Chief Legal Officer"},{"age":null,"name":"Mr. Saurabh  Sewak Ph.D.","title":"Vice President of Corporate Development"}],"industry":"Biotechnology","irWebsite":"","website":"https://foghorntx.com","phone":"617 586 3100"}}